Showing results (401-410 of 427) with videos related to
Sort By:
Pageof 43
Blood Cancer Journal|May 26, 2023
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcomeJulia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, et al.Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 20, 2017
European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14W Uter, J C Amario-Hita, A Balato, et al.The Lancet. Haematology|April 7, 2024
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.Blood|July 30, 2025
Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trialMatthias Stelljes, Jan Moritz Middeke, Gesine Bug, et al.Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.Pageof 43